Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,430

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Thyroid cancer

Open access
Cabanillas, Maria E, McFadden, David G, Durante, Cosimo·2016·The Lancet
DOI 10.1016/s0140-6736(16)30172-6
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(16)30172-6

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 95

  1. Davies, 2010, The increasing incidence of small thyroid cancers: where are the cases coming from?, Laryngoscope, 120, 2446, 10.1002/lary.21076 · DOI
  2. Sosa, 2013, Increases in thyroid nodule fine-needle aspirations, operations, and diagnoses of thyroid cancer in the United States, Surgery, 154, 1420, 10.1016/j.surg.2013.07.006 · DOI
  3. Smith-Bindman, 2013, Risk of thyroid cancer based on thyroid ultrasound imaging characteristics: results of a population-based study, JAMA Intern Med, 173, 1788, 10.1001/jamainternmed.2013.9245 · DOI · Paper page
  4. Papini, 2002, Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-doppler features, J Clin Endocrinol Metab, 87, 1941, 10.1210/jcem.87.5.8504 · DOI · Paper page
  5. Durante, 2015, The natural history of benign thyroid nodules, JAMA, 313, 926, 10.1001/jama.2015.0956 · DOI · Paper page
  6. Filetti, 2006, Nonsurgical approaches to the management of thyroid nodules, Nat Clin Pract Endocrinol Metab, 2, 384, 10.1038/ncpendmet0215 · DOI
  7. Wells, 2015, Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma, Thyroid, 25, 567, 10.1089/thy.2014.0335 · DOI
  8. Moley, 2010, Medullary thyroid carcinoma: management of lymph node metastases, J Natl Compr Canc Netw, 8, 549, 10.6004/jnccn.2010.0042 · DOI
  9. 2014, Integrated genomic characterization of papillary thyroid carcinoma, Cell, 159, 676, 10.1016/j.cell.2014.09.050 · DOI
  10. Nikiforov, 2011, Molecular genetics and diagnosis of thyroid cancer, Nat Rev Endocrinol, 7, 569, 10.1038/nrendo.2011.142 · DOI · Paper page
  11. Raman, 2014, Pax-8-PPAR-gamma fusion protein in thyroid carcinoma, Nat Rev Endocrinol, 10, 616, 10.1038/nrendo.2014.115 · DOI
  12. Kelly, 2014, Identification of the transforming STRN–ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer, Proc Natl Acad Sci USA, 111, 4233, 10.1073/pnas.1321937111 · DOI · Paper page
  13. Hong DS, Farago AF, Brose MS, et al. Clinical safety and activity from a phase I study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions. 97th Annual Meeting of the American Association for Cancer Research; New Orleans, LA; April 16–20, 2016. Abstract CT008. · DOI
  14. Godbert, 2015, Remarkable response to crizotinib in woman with anaplastic lymphoma kinase-rearranged anaplastic thyroid carcinoma, J Clin Oncol, 33, e84, 10.1200/JCO.2013.49.6596 · DOI
  15. Elisei, 2008, BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study, J Clin Endocrinol Metab, 93, 3943, 10.1210/jc.2008-0607 · DOI
  16. Xing, 2015, Association between BRAF V600E mutation and recurrence of papillary thyroid cancer, J Clin Oncol, 33, 42, 10.1200/JCO.2014.56.8253 · DOI
  17. Xing, 2013, Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer, JAMA, 309, 1493, 10.1001/jama.2013.3190 · DOI · Paper page
  18. Chen, 2016, BRAF(V600E) is correlated with recurrence of papillary thyroid microcarcinoma: a systematic review, multi-institutional primary data analysis, and meta-analysis, Thyroid, 26, 248, 10.1089/thy.2015.0391 · DOI
  19. Kowalska, 2016, Increase in papillary thyroid cancer incidence is accompanied by changes in the frequency of the BRAF mutation: a single-institution study, Thyroid, 26, 543, 10.1089/thy.2015.0352 · DOI
  20. Landa, 2013, Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease, J Clin Endocrinol Metab, 98, E1562, 10.1210/jc.2013-2383 · DOI · Paper page
  21. Liu, 2014, TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer, J Clin Endocrinol Metab, 99, E1130, 10.1210/jc.2013-4048 · DOI · Paper page
  22. Melo, 2014, TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas, J Clin Endocrinol Metab, 99, E754, 10.1210/jc.2013-3734 · DOI · Paper page
  23. Nikiforova, 2013, Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer, J Clin Endocrinol Metab, 98, E1852, 10.1210/jc.2013-2292 · DOI · Paper page
  24. Santarpia, 2008, Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer, J Clin Endocrinol Metab, 93, 278, 10.1210/jc.2007-1076 · DOI
  25. Hou, 2007, Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer, Clin Cancer Res, 13, 1161, 10.1158/1078-0432.CCR-06-1125 · DOI
  26. Ciampi, 2013, Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series, Thyroid, 23, 50, 10.1089/thy.2012.0207 · DOI
  27. Romei, 2015, Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?, Clin Endocrinol (Oxf), 82, 892, 10.1111/cen.12686 · DOI
  28. Romei, 2011, RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC), Clin Endocrinol (Oxf), 74, 241, 10.1111/j.1365-2265.2010.03900.x · DOI
  29. Brito, 2014, The accuracy of thyroid nodule ultrasound to predict thyroid cancer: systematic review and meta-analysis, J Clin Endocrinol Metab, 99, 1253, 10.1210/jc.2013-2928 · DOI · Paper page
  30. Kim, 2009, Sonographic features of follicular variant papillary thyroid carcinomas in comparison with conventional papillary thyroid carcinomas, J Ultrasound Med, 28, 1685, 10.7863/jum.2009.28.12.1685 · DOI
  31. Lubitz, 2010, Clinical and cytological features predictive of malignancy in thyroid follicular neoplasms, Thyroid, 20, 25, 10.1089/thy.2009.0208 · DOI
  32. Lee, 2013, Predictive factors of malignancy in thyroid nodules with a cytological diagnosis of follicular neoplasm, Endocr Pathol, 24, 177, 10.1007/s12022-013-9263-x · DOI
  33. Fukunari, 2004, Clinical evaluation of color doppler imaging for the differential diagnosis of thyroid follicular lesions, World J Surg, 28, 1261, 10.1007/s00268-004-7597-8 · DOI
  34. Miyakawa, 2005, Diagnosis of thyroid follicular carcinoma by the vascular pattern and velocimetric parameters using high resolution pulsed and power doppler ultrasonography, Endocr J, 52, 207, 10.1507/endocrj.52.207 · DOI
  35. Crippa, 2010, The Bethesda system for reporting thyroid fine-needle aspiration specimens, Am J Clin Pathol, 134, 343, 10.1309/AJCPXM9WIRQ8JZBJ · DOI
  36. Alexander, 2012, Preoperative diagnosis of benign thyroid nodules with indeterminate cytology, N Engl J Med, 367, 705, 10.1056/NEJMoa1203208 · DOI · Paper page
  37. Nikiforov, 2011, Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples, J Clin Endocrinol Metab, 96, 3390, 10.1210/jc.2011-1469 · DOI
  38. Nikiforov, 2015, Impact of the multi-gene ThyroSeq next-generation sequencing assay on cancer diagnosis in thyroid nodules with atypia of undetermined significance/follicular lesion of undetermined significance cytology, Thyroid, 25, 1217, 10.1089/thy.2015.0305 · DOI
  39. Nikiforov, 2014, Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay, Cancer, 120, 3627, 10.1002/cncr.29038 · DOI · Paper page
  40. Alexander, 2014, Multicenter clinical experience with the Afirma gene expression classifier, J Clin Endocrinol Metab, 99, 119, 10.1210/jc.2013-2482 · DOI
  41. Harrell, 2014, Surgical utility of Afirma: effects of high cancer prevalence and oncocytic cell types in patients with indeterminate thyroid cytology, Endocr Pract, 20, 364, 10.4158/EP13330.OR · DOI
  42. McIver, 2014, An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules, J Clin Endocrinol Metab, 99, 4069, 10.1210/jc.2013-3584 · DOI
  43. Marti, 2015, Wide inter-institutional variation in performance of a molecular classifier for indeterminate thyroid nodules, Ann Surg Oncol, 22, 3996, 10.1245/s10434-015-4486-3 · DOI
  44. Kouvaraki, 2003, Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer, Surgery, 134, 946, 10.1016/S0039-6060(03)00424-0 · DOI · Paper page
  45. O'Connell, 2013, The utility of routine preoperative cervical ultrasonography in patients undergoing thyroidectomy for differentiated thyroid cancer, Surgery, 154, 697, 10.1016/j.surg.2013.06.040 · DOI
  46. Haigh, 2005, Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer, Ann Surg Oncol, 12, 81, 10.1007/s10434-004-1165-1 · DOI
  47. Mendelsohn, 2010, Surgery for papillary thyroid carcinoma: is lobectomy enough?, Arch Otolaryngol Head Neck Surg, 136, 1055, 10.1001/archoto.2010.181 · DOI · Paper page
  48. Barney, 2011, Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer, Head Neck, 33, 645, 10.1002/hed.21504 · DOI
  49. Adam, 2014, Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients, Ann Surg, 260, 601, 10.1097/SLA.0000000000000925 · DOI · Paper page
  50. Randolph, 2012, The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension, Thyroid, 22, 1144, 10.1089/thy.2012.0043 · DOI
  51. Hauch, 2014, Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons, Ann Surg Oncol, 21, 3844, 10.1245/s10434-014-3846-8 · DOI · Paper page
  52. Nixon, 2012, Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy, Surgery, 151, 571, 10.1016/j.surg.2011.08.016 · DOI
  53. Matsuzu, 2014, Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases, World J Surg, 38, 68, 10.1007/s00268-013-2224-1 · DOI
  54. Ito, 2010, An observational trial for papillary thyroid microcarcinoma in Japanese patients, World J Surg, 34, 28, 10.1007/s00268-009-0303-0 · DOI · Paper page
  55. Sugitani, 2010, Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes, World J Surg, 34, 1222, 10.1007/s00268-009-0359-x · DOI
  56. Brierley, 1997, A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example, Cancer, 79, 2414, 10.1002/(SICI)1097-0142(19970615)79:12<2414::AID-CNCR18>3.0.CO;2-U · DOI
  57. Orlov, 2009, Influence of age and primary tumor size on the risk for residual/recurrent well-differentiated thyroid carcinoma, Head Neck, 31, 782, 10.1002/hed.21020 · DOI
  58. Vaisman, 2011, Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer, Clin Endocrinol (Oxf), 75, 112, 10.1111/j.1365-2265.2011.04002.x · DOI
  59. Durante, 2012, Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement?, J Clin Endocrinol Metab, 97, 2748, 10.1210/jc.2012-1123 · DOI
  60. Tuttle, 2010, Thyroid, 20, 1341, 10.1089/thy.2010.0178 · DOI · Paper page
  61. Castagna, 2011, Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients, Eur J Endocrinol, 165, 441, 10.1530/EJE-11-0466 · DOI
  62. Pitoia, 2014, Biochemical persistence in thyroid cancer: is there anything to worry about?, Endocrine, 46, 532, 10.1007/s12020-014-0208-z · DOI
  63. Torlontano, 2003, Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer, Eur J Endocrinol, 148, 19, 10.1530/eje.0.1480019 · DOI
  64. Pacini, 2003, Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma, J Clin Endocrinol Metab, 88, 3668, 10.1210/jc.2002-021925 · DOI · Paper page
  65. Durante, 2011, Management of papillary thyroid cancer patients in absence of postoperative radioiodine remnant ablation: tailoring follow-up by neck sonography, J Clin Endocrinol Metab, 96, 3059, 10.1210/jc.2011-1379 · DOI
  66. Van Nostrand, 2009, The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer, Thyroid, 19, 1381, 10.1089/thy.2009.1611 · DOI
  67. Sawka, 2009, Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis, Thyroid, 19, 451, 10.1089/thy.2008.0392 · DOI
  68. Biondi, 2005, Thyroid-hormone therapy and thyroid cancer: a reassessment, Nat Clin Pract Endocrinol Metab, 1, 32, 10.1038/ncpendmet0020 · DOI
  69. Mazzaferri, 2001, Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer, J Clin Endocrinol Metab, 86, 1447, 10.1210/jcem.86.4.7407 · DOI · Paper page
  70. Jonklaas, 2006, Outcomes of patients with differentiated thyroid carcinoma following initial therapy, Thyroid, 16, 1229, 10.1089/thy.2006.16.1229 · DOI · Paper page
  71. Carhill, 2015, Long-term outcomes following therapy in differentiated thyroid carcinoma: NTCTCS registry analysis 1987–2012, J Clin Endocrinol Metab, 100, 3270, 10.1210/JC.2015-1346 · DOI · Paper page
  72. Durante, 2013, Papillary thyroid cancer: time course of recurrences during postsurgery surveillance, J Clin Endocrinol Metab, 98, 636, 10.1210/jc.2012-3401 · DOI · Paper page
  73. Meijer, 2010, Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis, Clin Endocrinol (Oxf), 72, 534, 10.1111/j.1365-2265.2009.03666.x · DOI
  74. Durante, 2006, Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy, J Clin Endocrinol Metab, 91, 2892, 10.1210/jc.2005-2838 · DOI
  75. Falchook, 2015, BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer, Thyroid, 25, 71, 10.1089/thy.2014.0123 · DOI
  76. Lorch, 2013, A phase II study of everolimus in patients with aggressive RAI refractory (RAIR) thyroid cancer (TC), Proc Am Soc Clin Oncol, 31, 6023, 10.1200/jco.2013.31.15_suppl.6023 · DOI
  77. Lim, 2013, A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes, Ann Oncol, 24, 3089, 10.1093/annonc/mdt379 · DOI
  78. Rothenberg, 2013, Re-differentiation of radioiodine-refractory BRAF V600E-mutant thyroid carcinoma with dabrafenib: a pilot study, Proc Am Soc Clin Oncol, 31, 6025, 10.1200/jco.2013.31.15_suppl.6025 · DOI
  79. Ho, 2013, Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer, N Engl J Med, 368, 623, 10.1056/NEJMoa1209288 · DOI · Paper page
  80. Cabanillas, 2014, A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer, Thyroid, 24, 1508, 10.1089/thy.2014.0125 · DOI
  81. Shah, 2015, Cabozantinib in patients with radioiodine-refractory differentiated thyroid cancer who progressed on prior VEGFR-targeted therapy: results of NCI- and ITOG-sponsored multicenter phase II clinical trial, Thyroid, 25, 73
  82. Bible, 2010, Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study, Lancet Oncol, 11, 962, 10.1016/S1470-2045(10)70203-5 · DOI · Paper page
  83. Carr, 2010, Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation, Clin Cancer Res, 16, 5260, 10.1158/1078-0432.CCR-10-0994 · DOI · Paper page
  84. Brose, 2014, Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial, Lancet, 384, 319, 10.1016/S0140-6736(14)60421-9 · DOI
  85. Schlumberger, 2015, Lenvatinib versus placebo in radioiodine-refractory thyroid cancer, N Engl J Med, 372, 621, 10.1056/NEJMoa1406470 · DOI · Paper page
  86. Wells, 2012, Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial, J Clin Oncol, 30, 134, 10.1200/JCO.2011.35.5040 · DOI · Paper page
  87. Elisei, 2013, Cabozantinib in progressive medullary thyroid cancer, J Clin Oncol, 31, 3639, 10.1200/JCO.2012.48.4659 · DOI · Paper page
  88. Brose, 2015, Effect of age and lenvatinib treatment on overall survival for patients with 131I-refractory differentiated thyroid cancer in SELECT, Proc Am Soc Clin Oncol, 33, 6048, 10.1200/jco.2015.33.15_suppl.6048 · DOI
  89. Schlumberger, 2015, Final overall survival analysis of EXAM, an international, double-blind, randomized, placebo-controlled phase III trial of cabozantinib (Cabo) in medullary thyroid carcinoma (MTC) patients with documented RECIST progression at baseline, Proc Am Soc Clin Oncol, 33, 6012, 10.1200/jco.2015.33.15_suppl.6012 · DOI
  90. Cabanillas, 2015, Thyroid gland malignancies, Hematol Oncol Clin North Am, 29, 1123, 10.1016/j.hoc.2015.07.011 · DOI
  91. Smallridge, 2012, American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer, Thyroid, 22, 1104, 10.1089/thy.2012.0302 · DOI · Paper page
  92. Takahashi, 2013, Phase II study of lenvatinib, a multitargeted tyrosine kinase inhibitor, in patients with all histologic subtypes of advanced thyroid cancer (differentiated, medullary, and anaplastic), Ann Oncol, 24, iv340
  93. Ross, 2009, Recurrence after treatment of micropapillary thyroid cancer, Thyroid, 19, 1043, 10.1089/thy.2008.0407 · DOI
  94. Dadu, 2014, Efficacy and tolerability of vemurafenib in patients with BRAF-positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience, J Clin Endocrinol Metab, 100, E77, 10.1210/jc.2014-2246 · DOI
  95. Dadu, 2015, Immune markers in medullary thyroid cancer (MTC) and their clinical significance, Thyroid, 25, 491

Cited by

See all 1,430

Metadata

Authors
Cabanillas, M. E., McFadden, D. G., & Durante, C.
Venue
The Lancet
Publisher
Elsevier BV
Published
2016-12
Volume
388
Issue
10061
Pages
2783-2795
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
DOI
10.1016/s0140-6736(16)30172-6
OpenAlex
W4211213741
Cited by
1,430
References
5
FWCI
54.27
Type
journal article
Language
en
Open access
bronze
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.